Monoammonium-glycyrrhizinate-hydrate - Terpenoids and Glycoside - 生命科学试剂 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEMonoammonium glycyrrhizinate hydrateCat. No.: HY-76225CAS No.: 53956-04-0分式: CHNO分量: 839.96作靶点: Others作通路: Others储存式: Powder -20C 3 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 100 mg/mL (119.05 mM)* means soluble,

2、but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 1.1905 mL 5.9527 mL 11.9053 mL5 mM 0.2381 mL 1.1905 mL 2.3811 mL10 mM 0.1191 mL 0.5953 mL 1.1905 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。体内实验 请根据您的实验动物和给药式选择适当的溶解案，配制前请先配制澄清的储备液，再依次添加助溶剂(为保证实验结果的可靠性，体内实验的作液，建议您现现配，当天使；澄清

3、的储备液可以根据储存条件，适当保存；以下溶剂前的百分 指该溶剂在您配制终溶液中的体积占)：1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (2.98 mM); Clear solution2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (2.98 mM); Clear solution3. 请依序添加每种溶剂： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL

4、 (2.98 mM); Clear solution1/2 Master of Small Molecules 您边的抑制剂师www.MedChemEBIOLOGICAL ACTIVITY物活性 Monoammonium glycyrrhizinate hydrate 具有抗炎、抗过敏、抗胃溃疡、抗肝炎等药理活性。体内研究 The increase of the lung W/D weight ratios is significantly reduced by high and medium dose of MAG (10 and30mg/kg) administration. Pretre

5、atment with MAG (10 and 30mg/kg) efficiently reduces the production of TNF- and IL-1. MAG (10, 30mg/kg) significantly decreases NF-On the contrary, LPS significantly reduces IB-B p65 protein expression, compared with LPS.whereas MAG (10 and 30mg/kg) significantly increased IB-protein expression comp

6、ared with the control group,expression, compared with the LPS group 1. Low- and high-dose MAG treatment significantly reduces the AST, ALT, TBIL, and TBA levels at 14 and 21 dtime points when compared with that of the RIF and INH group, suggesting the protective effect of MAG onRIF- and INH-induced

7、liver injury. MAG treatment groups elevate the hepatic GSH level at 7, 14, and 21 dtime points and markedly reduce the MDA level at 14 and 21 d time points in RIF- and INH-treated rats,suggesting the protective effect of MAG in RIF- and INH induced liver injuries 2.PROTOCOLAnimal Mice 1Administratio

8、n 12 In this study, BALB/c mice (male, 6-8weeks old, and 20-25 g) are used. Mice are randomly divided into fivegroups: control group, LPS group, and LPS + Monoammonium glycyrrhizinate (MAG: 3, 10, and 30mg/kg)groups. Each group contains eight mice. Mice are anesthetized with intraperitoneal injectio

9、n of sodiumpentobarbital (50mg/kg). Before inducing acute lung injury, the mice are given intraperitoneal injection withMAG (3, 10, and 30mg/kg). One hour later, LPS (5mg/kg) is instilled intratracheally to induce acute lunginjury. Normal mice are given PBS 1.Rats 2Male Wistar rats (180-220 g) are u

10、sed. Rats are randomly divided into four groups, i.e., control group, RIFand INH group, MAG low-dose group, and MAG high-dose group, each group has 15 rats. Rats in the RIFand INH group receive RIF (60 mg/kg) and INH (60 mg/kg) by gavage administration once daily; rats in MAGgroups are pretreated wi

11、th MAG at the doses of 45 or 90 mg/kg, RIF (60 mg/kg) and INH (60 mg/kg) aregiven 3 h after MAG administration; rats in the control group are treated with saline. To evaluate the dynamiceffect of drugs, rats in each group are sacrificed on 7, 14, and 21 d after drug administration 2.MCE has not inde

12、pendently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Huang X, et al. Anti-Inflammatory Effects of Monoammonium Glycyrrhizinate on Lipopolysaccharide-Induced Acute Lung Injury in Micethrough Regulating Nuclear Factor-Kappa B Signaling Pathway. Evid Based Complement Alternat Med. 2015;2015:272474.2. Zhou L, et al. Monoammonium glycyrrhizinate protects rifampicin- and isoniazid-induced hepatotoxicity via regulating the expression oftransporter Mrp2, Ntcp, and Oatp1a4 in liver. Pharm Biol. 2016;54(6):931-7.McePdfHeig